Cyclooxygenase-selective inhibition of prostanoid formation: Transducing biochemical selectivity into clinical read-outs

Journal of Clinical Investigation

Volumn 108, Issue 1, 2001, Pages 7-13

  Patrono, C ^a   Patrignani, P ^a   Garcia Rodriguez L A ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXY 2 NAPHTHYLACETIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ROFECOXIB;

ARTERY THROMBOSIS; CANCER PREVENTION; COLORECTAL CANCER; DRUG SPECIFICITY; ENZYME INHIBITION; GASTRODUODENAL ULCER; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS PREVENTION; ULCER HEALING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DEPRESSION, CHEMICAL; DINOPROSTONE; EPOPROSTENOL; GASTRIC MUCOSA; GASTROINTESTINAL HEMORRHAGE; HUMANS; INCIDENCE; INTESTINAL MUCOSA; ISOENZYMES; LACTONES; MEMBRANE PROTEINS; PEPTIC ULCER; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS; SUBSTRATE SPECIFICITY; SULFONAMIDES; SULFONES; THROMBOEMBOLISM; THROMBOXANE A2; TREATMENT OUTCOME;

EID: 0034946873     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200113418     Document Type: Review

References (31)

1. Aspirin as an antiplatelet drug
2. The anti-inflammatory properties and safety of coxibs, selective inhibitors of cyclooxygenase-2
3. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs
4. Regulated formation of eicosanoids
5. Estimated rate of thromboxane secretion into the circulation of normal man
6. Platelet-active drugs: The relationships among dose, effectiveness, and side effects
7. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man
8. Prevention of death, myocardial infarction and stroke by antiplatelet therapy: Collaborative meta-analysis of 266 trials involving 200,000 patients at high risk of occlusive vascular events
9. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomised controlled trial
10. Acetylation of prostaglandin synthase by aspirin
11. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects
12. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other anti-hypertensive drugs
13. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs
14. Rofecoxib [Vioxx, MK-0966; 4-(4'Methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
15. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
16. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs
17. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
18. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial
19. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
20. The relative risk of upper gastrointestinal complications among users of acetaminophen and non-steroidal anti-inflammatory drugs
21. Chemoprevention of colorectal cancer
22. Cyclooxygenase-2 and carcinogenesis
23. Is cyclooxygenase-2 the alpha and the omega in cancer?
24. Reduced incidence ofcolorectal adenoma among long-term users of nonsteroidal anti-inflammatory drugs: A pooled analysis of published studies and a new population-based study
25. Reduced risk of colorectal cancer among long-term users of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs
26. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice
27. Regulated expression of the two cyclooxygenase isoforms in a human syndrome of inflammation
28. Renal effects of COX-2 selective inhibitors
29. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases
30. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics
31. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects